Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease
- 1 September 1997
- journal article
- research article
- Published by Wiley in Drug Development Research
Abstract
No abstract availableKeywords
This publication has 109 references indexed in Scilit:
- Concentration-Effect Relationship of Levodopa in Patients with Parkinson's DiseaseClinical Pharmacokinetics, 1995
- Acute Effects of COMT Inhibition on L-DOPA Pharmacokinetics in Patients Treated with Carbidopa and SelegilineClinical Neuropharmacology, 1995
- Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvementNeuroscience Letters, 1995
- Acute Administration of Levodopa-Benserazide and Tolcapone, a COMT Inhibitor, in Parkinsonʼs DiseaseClinical Neuropharmacology, 1995
- Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated miceJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1995
- General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferaseGeneral Pharmacology: The Vascular System, 1994
- Therapy with central active catechol-O-methyltransferase (COMT)-inhibitors: is addition of monoamine oxidase (MAO)-inhibitors necessary to slow progress of neurodegenerative disorders?Journal Of Neural Transmission-Parkinsons Disease and Dementia Section, 1993
- Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferaseLife Sciences, 1988
- Clinical Pharmacokinetics of Anti-Parkinsonian DrugsClinical Pharmacokinetics, 1987
- 3-0-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrierLife Sciences, 1975